Search research articles
Contact Us
Filters
Showing results (31-40 of 82) with videos related to
Page
of 9
Sort By:
British Journal of Haematology
|
July 31, 2025
Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study
Maximilian Schönung, Silvia Rathmann, Senthilkumar Ramamoorthy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2023
Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial
Birgit Geoerger, Lynley V Marshall, Karsten Nysom, et al.
Nature Communications
|
February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
Jaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
The New England Journal of Medicine
|
April 26, 2023
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
Inge M van der Sluis, Paola de Lorenzo, Rishi S Kotecha, et al.
Frontiers in Pediatrics
|
May 8, 2018
Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
Olga Østrup, Karsten Nysom, David Scheie, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 20, 2014
The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents
Veronika Dunkl, Corvin Cleff, Gabriele Stoffels, et al.
JCO Precision Oncology
|
May 25, 2022
Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK</i> Oncogenic Fusion
Anne Thorwarth, Kerstin Haase, Claudia Röefzaad, et al.
Pediatric Blood & Cancer
|
January 7, 2024
The ECHO recommendations for dealing with vinblastine shortage affecting standard treatment of systemic Langerhans cell histiocytosis
Vassilios Papadakis, Itziar Astigarraga, Cor van den Bos, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2022
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M Loeb, Ji Won Lee, Daniel A Morgenstern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2026
Sustained Benefit of Blinatumomab in Infants With <i>KMT2A</i>-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics
Miguel Vieira Martins, Paola de Lorenzo, Rishi S Kotecha, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 82) with videos related to
Sort By:
Page
of 9
British Journal of Haematology
|
July 31, 2025
Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study
Maximilian Schönung, Silvia Rathmann, Senthilkumar Ramamoorthy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2023
Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial
Birgit Geoerger, Lynley V Marshall, Karsten Nysom, et al.
Nature Communications
|
February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
Jaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
The New England Journal of Medicine
|
April 26, 2023
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
Inge M van der Sluis, Paola de Lorenzo, Rishi S Kotecha, et al.
Frontiers in Pediatrics
|
May 8, 2018
Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
Olga Østrup, Karsten Nysom, David Scheie, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 20, 2014
The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents
Veronika Dunkl, Corvin Cleff, Gabriele Stoffels, et al.
JCO Precision Oncology
|
May 25, 2022
Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK</i> Oncogenic Fusion
Anne Thorwarth, Kerstin Haase, Claudia Röefzaad, et al.
Pediatric Blood & Cancer
|
January 7, 2024
The ECHO recommendations for dealing with vinblastine shortage affecting standard treatment of systemic Langerhans cell histiocytosis
Vassilios Papadakis, Itziar Astigarraga, Cor van den Bos, et al.
Cancer Immunology, Immunotherapy : CII
|
March 9, 2022
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial
David M Loeb, Ji Won Lee, Daniel A Morgenstern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2026
Sustained Benefit of Blinatumomab in Infants With <i>KMT2A</i>-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics
Miguel Vieira Martins, Paola de Lorenzo, Rishi S Kotecha, et al.
Page
of 9